ERBB2 and neoplasm: More women with HER2-positive and triple-negative tumours were treated with chemotherapy, possibly due to a strong push from the oncologists based on data which consistently show chemo-benefits even in patients with small node-negative, triple-negative, and HER2-positive tumours [7,25,26,27].